Who are Ofatumumab combined with daratumumab's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): daclizumab, infliximab, Casirivimab and Imdevimab Drug Combination, Lilly Bamlanivimab + Etesevimab, Trastuzumab + Pertuzumab, Pertuzumab + trastuzumab, Regeneron Casirivimab + Imdevimab.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/ofatumumab-combined-with-daratumumab.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Ofatumumab combined with daratumumab — Competitive Intelligence Brief

Ofatumumab combined with daratumumab (Ofatumumab combined with daratumumab) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Monoclonal antibody combination. Area: Oncology.

phase 3 Monoclonal antibody combination CD20 (ofatumumab) and CD38 (daratumumab) Oncology Small molecule Live · refreshed every 30 min

Target snapshot

Ofatumumab combined with daratumumab (Ofatumumab combined with daratumumab) — The First People's Hospital of Changzhou. Ofatumumab and daratumumab are monoclonal antibodies that work synergistically to target and eliminate malignant B cells and plasma cells by binding to CD20 and CD38 respectively, triggering immune-mediated cell death.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Ofatumumab combined with daratumumab TARGET	Ofatumumab combined with daratumumab	The First People's Hospital of Changzhou	phase 3	Monoclonal antibody combination	CD20 (ofatumumab) and CD38 (daratumumab)
daclizumab, infliximab	daclizumab, infliximab	University of Iowa	marketed	Monoclonal antibody combination	IL-2 receptor alpha (CD25) and TNF-alpha
Casirivimab and Imdevimab Drug Combination	Casirivimab and Imdevimab Drug Combination	Mansoura University Hospital	marketed	Monoclonal antibody combination (SARS-CoV-2 neutralizing antibodies)	SARS-CoV-2 spike protein receptor-binding domain
Lilly Bamlanivimab + Etesevimab	Lilly Bamlanivimab + Etesevimab	Erin McCreary	marketed	Monoclonal antibody combination (neutralizing antibodies)	SARS-CoV-2 spike protein receptor-binding domain
Trastuzumab + Pertuzumab	Trastuzumab + Pertuzumab	Massachusetts General Hospital	marketed	HER2-targeted monoclonal antibody combination	HER2 (human epidermal growth factor receptor 2)
Pertuzumab + trastuzumab	Pertuzumab + trastuzumab	European Organisation for Research and Treatment of Cancer - EORTC	marketed	HER2-targeted monoclonal antibody combination	HER2 (human epidermal growth factor receptor 2)
Regeneron Casirivimab + Imdevimab	Regeneron Casirivimab + Imdevimab	Erin McCreary	marketed	Monoclonal antibody combination (neutralizing antibodies)	SARS-CoV-2 spike protein

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Monoclonal antibody combination class)

AstraZeneca · 1 drug in this class
National Institute of Allergy and Infectious Diseases (NIAID) · 1 drug in this class
The First People's Hospital of Changzhou · 1 drug in this class
University of Iowa · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Ofatumumab combined with daratumumab — Competitive Intelligence Brief. https://druglandscape.com/ci/ofatumumab-combined-with-daratumumab. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab